Item Type | Name |
Concept
|
Acute Disease
|
Concept
|
Actins
|
Concept
|
Adenocarcinoma
|
Concept
|
Adenoviridae
|
Concept
|
Antibiotics, Antineoplastic
|
Concept
|
Antibodies, Neoplasm
|
Concept
|
Antibodies, Viral
|
Concept
|
Antigen-Presenting Cells
|
Concept
|
Calcium-Transporting ATPases
|
Concept
|
Blood Pressure
|
Concept
|
Bone Marrow Cells
|
Concept
|
Amino Acid Sequence
|
Concept
|
Administration, Oral
|
Concept
|
Body Fluids
|
Concept
|
Antigens, Differentiation
|
Concept
|
Antineoplastic Agents
|
Concept
|
Cell Line, Transformed
|
Concept
|
Aminopyridines
|
Concept
|
Anemia
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
Concept
|
Anal Canal
|
Concept
|
Analysis of Variance
|
Concept
|
Anemia, Hemolytic, Autoimmune
|
Concept
|
Antibodies, Anti-Idiotypic
|
Concept
|
Antibodies, Monoclonal
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
Concept
|
Colostomy
|
Concept
|
Ascitic Fluid
|
Concept
|
Cyclosporins
|
Concept
|
Cytoplasmic Granules
|
Concept
|
Histocompatibility Antigens Class II
|
Concept
|
B-Lymphocytes
|
Concept
|
Base Sequence
|
Concept
|
Benzamides
|
Concept
|
Carmustine
|
Concept
|
Cell Nucleus
|
Concept
|
Cervical Vertebrae
|
Concept
|
DNA Damage
|
Concept
|
Cholera Toxin
|
Concept
|
Carcinoma, Renal Cell
|
Concept
|
Autoantibodies
|
Concept
|
Drainage
|
Concept
|
Bifidobacterium
|
Concept
|
Biopsy
|
Concept
|
Urinary Bladder Neoplasms
|
Concept
|
Bone Marrow
|
Concept
|
Carbon Monoxide
|
Concept
|
Carcinoma, Basal Cell
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Cell Membrane
|
Concept
|
Cell Division
|
Concept
|
Cell Separation
|
Concept
|
Clone Cells
|
Concept
|
Colitis
|
Concept
|
Complement System Proteins
|
Concept
|
Cell-Free System
|
Concept
|
Foreign Bodies
|
Concept
|
Colonic Neoplasms
|
Concept
|
Genetic Vectors
|
Concept
|
Ciprofloxacin
|
Concept
|
Classification
|
Concept
|
C-Reactive Protein
|
Concept
|
Colony-Stimulating Factors
|
Concept
|
Contrast Media
|
Concept
|
Cytosol
|
Concept
|
Herpesviridae
|
Concept
|
Dacarbazine
|
Concept
|
Immune System
|
Concept
|
Cycloheximide
|
Concept
|
Cytological Techniques
|
Concept
|
Dexamethasone
|
Concept
|
Dendritic Cells
|
Concept
|
Deoxyglucose
|
Concept
|
Diarrhea
|
Concept
|
Diet
|
Concept
|
Inositol Phosphates
|
Concept
|
Interleukin-2
|
Concept
|
Interleukins
|
Concept
|
Endothelium, Vascular
|
Concept
|
Cytoskeleton
|
Concept
|
Cytotoxicity, Immunologic
|
Concept
|
DNA Repair
|
Concept
|
Dose-Response Relationship, Radiation
|
Concept
|
Cause of Death
|
Concept
|
Chemotaxis, Leukocyte
|
Concept
|
DNA, Neoplasm
|
Concept
|
Cytotoxicity Tests, Immunologic
|
Concept
|
Glucocorticoids
|
Concept
|
Graft Survival
|
Concept
|
Growth Inhibitors
|
Concept
|
Kidney Neoplasms
|
Concept
|
Enzyme Inhibitors
|
Concept
|
Immunity, Active
|
Concept
|
Chronic Disease
|
Concept
|
Exons
|
Concept
|
Extracellular Space
|
Concept
|
Eye Neoplasms
|
Concept
|
Cost-Benefit Analysis
|
Concept
|
Double-Blind Method
|
Concept
|
Diterpenes
|
Concept
|
Drug Evaluation, Preclinical
|
Concept
|
Drug Therapy, Combination
|
Concept
|
Interferons
|
Concept
|
Enzyme Activation
|
Concept
|
Mice, Inbred C3H
|
Concept
|
Gene Expression Regulation
|
Concept
|
Exudates and Transudates
|
Concept
|
Mycoplasma Infections
|
Concept
|
Feasibility Studies
|
Concept
|
Killer Cells, Natural
|
Concept
|
Graft Rejection
|
Concept
|
Oncogenes
|
Concept
|
Genetic Engineering
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
Concept
|
Hypertrophy
|
Concept
|
Immune Sera
|
Concept
|
Liver Neoplasms
|
Concept
|
Patient Care Planning
|
Concept
|
Enterostomy
|
Concept
|
Enzyme-Linked Immunosorbent Assay
|
Concept
|
Enzyme Induction
|
Concept
|
Flow Cytometry
|
Concept
|
Fluorescent Antibody Technique
|
Concept
|
Infusions, Intravenous
|
Concept
|
Interleukin-1
|
Concept
|
Gene Amplification
|
Concept
|
Isoenzymes
|
Concept
|
Multigene Family
|
Concept
|
Leukocytes, Mononuclear
|
Concept
|
Medicare
|
Concept
|
Macrophages
|
Concept
|
Mandible
|
Concept
|
Peptidyl-Dipeptidase A
|
Concept
|
Membrane Glycoproteins
|
Concept
|
Metformin
|
Concept
|
Lymphocyte Culture Test, Mixed
|
Concept
|
Leukocytes
|
Concept
|
Mice, Inbred A
|
Concept
|
Mice, Inbred Strains
|
Concept
|
Microfilament Proteins
|
Concept
|
Pilot Projects
|
Concept
|
Lymphopenia
|
Concept
|
Mice, Inbred CBA
|
Concept
|
Mice, Transgenic
|
Concept
|
Pneumonia, Viral
|
Concept
|
Extracellular Matrix
|
Concept
|
Immunoglobulin Variable Region
|
Concept
|
Immunohistochemistry
|
Concept
|
Molecular Sequence Data
|
Concept
|
Glycolysis
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Mesothelioma
|
Concept
|
Mice, Inbred BALB C
|
Concept
|
Mice, Inbred C57BL
|
Concept
|
Mice, Nude
|
Concept
|
Mutation
|
Concept
|
Cricetinae
|
Concept
|
Hot Temperature
|
Concept
|
Interleukin-3
|
Concept
|
Wilms Tumor
|
Concept
|
Leukemia L1210
|
Concept
|
Peritoneal Cavity
|
Concept
|
Phosphatidylinositols
|
Concept
|
Ovalbumin
|
Concept
|
Lipopolysaccharides
|
Concept
|
Lung Neoplasms
|
Concept
|
Lymphokines
|
Concept
|
Major Histocompatibility Complex
|
Concept
|
Oocytes
|
Concept
|
Osteochondritis
|
Concept
|
Parietal Lobe
|
Concept
|
Morpholines
|
Concept
|
Oxygen
|
Concept
|
Premedication
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Piperazines
|
Concept
|
Protein Processing, Post-Translational
|
Concept
|
Protein Synthesis Inhibitors
|
Concept
|
Pyridines
|
Concept
|
Forecasting
|
Concept
|
Histocompatibility Antigens
|
Concept
|
Hodgkin Disease
|
Concept
|
Recurrence
|
Concept
|
Guanine
|
Concept
|
H-2 Antigens
|
Concept
|
Health Resources
|
Concept
|
Repressor Proteins
|
Concept
|
Risk Factors
|
Concept
|
Radiography
|
Concept
|
Receptors, Antigen, B-Cell
|
Concept
|
Interferon-gamma
|
Concept
|
Intestinal Mucosa
|
Concept
|
Cohort Studies
|
Concept
|
Genes, ras
|
Concept
|
Reagent Kits, Diagnostic
|
Concept
|
Regulatory Sequences, Nucleic Acid
|
Concept
|
HLA-A2 Antigen
|
Concept
|
Interleukin-6
|
Concept
|
Spermatogonia
|
Concept
|
Ribonuclease, Pancreatic
|
Concept
|
RNA Processing, Post-Transcriptional
|
Concept
|
Humans
|
Concept
|
Immunization
|
Concept
|
Incidence
|
Concept
|
Cluster Analysis
|
Concept
|
Tomography, X-Ray Computed
|
Concept
|
Transcription, Genetic
|
Concept
|
Protein Biosynthesis
|
Concept
|
Sunlight
|
Concept
|
Specific Pathogen-Free Organisms
|
Concept
|
Informed Consent
|
Concept
|
Interferon Type I
|
Concept
|
Thrombosis
|
Concept
|
CHO Cells
|
Concept
|
Syndrome
|
Concept
|
Tumor Necrosis Factor-alpha
|
Concept
|
Clinical Trials, Phase I as Topic
|
Concept
|
Testis
|
Concept
|
Drug Design
|
Concept
|
Protein Engineering
|
Concept
|
HLA-A Antigens
|
Concept
|
Ketoconazole
|
Concept
|
Vaccination
|
Concept
|
CD28 Antigens
|
Concept
|
Octreotide
|
Concept
|
Histocompatibility Antigens Class I
|
Concept
|
Lymphoid Tissue
|
Concept
|
Lymphoma, Follicular
|
Concept
|
Mandibular Diseases
|
Concept
|
Transduction, Genetic
|
Concept
|
Herpesvirus 1, Human
|
Concept
|
Adenocarcinoma, Clear Cell
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
Concept
|
Th1 Cells
|
Concept
|
Trans-Activators
|
Concept
|
Randomized Controlled Trials as Topic
|
Concept
|
Risk Assessment
|
Concept
|
Cell Culture Techniques
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Antibodies, Blocking
|
Concept
|
Radiopharmaceuticals
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
Concept
|
Caspases
|
Concept
|
Guanine Nucleotide Exchange Factors
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Mitogen-Activated Protein Kinases
|
Concept
|
Transforming Growth Factor beta
|
Concept
|
NF-kappa B
|
Concept
|
Osteonectin
|
Concept
|
Cell Adhesion Molecules
|
Concept
|
Up-Regulation
|
Concept
|
8-Bromo Cyclic Adenosine Monophosphate
|
Concept
|
Mice, Inbred DBA
|
Concept
|
PC12 Cells
|
Concept
|
CD8 Antigens
|
Concept
|
Muromonab-CD3
|
Concept
|
Receptors, Interleukin-2
|
Concept
|
Antigens, CD
|
Concept
|
Lymph Nodes
|
Concept
|
Macrophage Activation
|
Concept
|
Mitochondria
|
Concept
|
Leukemia, Myeloid, Acute
|
Concept
|
CD4-Positive T-Lymphocytes
|
Concept
|
Interleukin-4
|
Concept
|
Immunotherapy, Adoptive
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
Concept
|
Paclitaxel
|
Concept
|
Cytochalasin D
|
Concept
|
Gene Expression
|
Concept
|
Drug Approval
|
Concept
|
Lymphocyte Function-Associated Antigen-1
|
Concept
|
T-Lymphocyte Subsets
|
Concept
|
RNA Interference
|
Concept
|
Methionine
|
Concept
|
Treatment Outcome
|
Concept
|
Point Mutation
|
Concept
|
Guidelines as Topic
|
Concept
|
Interferon-alpha
|
Concept
|
Gene Transfer Techniques
|
Concept
|
Gene Deletion
|
Concept
|
B7-1 Antigen
|
Concept
|
Mice, Knockout
|
Concept
|
CD8-Positive T-Lymphocytes
|
Concept
|
Cell Proliferation
|
Concept
|
Chemokines
|
Concept
|
CD40 Antigens
|
Concept
|
Disease Progression
|
Concept
|
ras Proteins
|
Concept
|
Interleukin-12
|
Concept
|
Basic-Leucine Zipper Transcription Factors
|
Concept
|
Apoptosis Regulatory Proteins
|
Concept
|
Th2 Cells
|
Concept
|
Models, Immunological
|
Concept
|
beta Catenin
|
Concept
|
Fluorodeoxyglucose F18
|
Concept
|
Antineoplastic Agents, Alkylating
|
Concept
|
L-Selectin
|
Concept
|
Transgenes
|
Concept
|
Needs Assessment
|
Concept
|
Angiogenesis Inhibitors
|
Concept
|
Cancer Vaccines
|
Concept
|
Kv1.3 Potassium Channel
|
Concept
|
Fas Ligand Protein
|
Concept
|
Tumor Necrosis Factor Receptor Superfamily, Member 9
|
Concept
|
Gene Regulatory Networks
|
Concept
|
ras Guanine Nucleotide Exchange Factors
|
Concept
|
MAP Kinase Kinase Kinases
|
Concept
|
Chemokines, CC
|
Concept
|
Diacylglycerol Kinase
|
Concept
|
Interleukin-23
|
Concept
|
Papillomavirus Vaccines
|
Concept
|
Chemokine CXCL9
|
Concept
|
Lymphocyte Count
|
Concept
|
Immunoconjugates
|
Concept
|
src Homology Domains
|
Concept
|
Antineoplastic Agents, Hormonal
|
Concept
|
Jurkat Cells
|
Concept
|
Protein Tyrosine Phosphatases
|
Concept
|
Parietal Bone
|
Concept
|
Gene Knockout Techniques
|
Concept
|
GTP Phosphohydrolases
|
Concept
|
Mastocytoma
|
Concept
|
Receptors, Purinergic P2X7
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
B7-H1 Antigen
|
Concept
|
Programmed Cell Death 1 Ligand 2 Protein
|
Concept
|
Lymphatic Vessels
|
Concept
|
Consensus
|
Concept
|
PPAR gamma
|
Concept
|
MAP Kinase Kinase 4
|
Concept
|
Positron-Emission Tomography
|
Concept
|
Systems Biology
|
Concept
|
Chromatin Immunoprecipitation
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Biological Specimen Banks
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p16
|
Concept
|
Proto-Oncogene Proteins B-raf
|
Concept
|
Indoleamine-Pyrrole 2,3,-Dioxygenase
|
Concept
|
Caspase 1
|
Concept
|
Proto-Oncogene Proteins c-kit
|
Concept
|
Internet
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
Concept
|
Quality-Adjusted Life Years
|
Concept
|
Adoptive Transfer
|
Concept
|
Active Transport, Cell Nucleus
|
Concept
|
Access to Information
|
Concept
|
Evidence-Based Medicine
|
Concept
|
Papillomaviridae
|
Concept
|
Gene Expression Profiling
|
Concept
|
Interferon Regulatory Factor-3
|
Concept
|
bcl-X Protein
|
Concept
|
Farnesyltranstransferase
|
Concept
|
Type C Phospholipases
|
Concept
|
Physicians
|
Concept
|
Piperidines
|
Concept
|
Promoter Regions, Genetic
|
Concept
|
Mice
|
Concept
|
CD47 Antigen
|
Concept
|
Pyrimidines
|
Concept
|
Tumor Necrosis Factor Ligand Superfamily Member 14
|
Concept
|
4-1BB Ligand
|
Concept
|
Pyrroles
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Saliva
|
Concept
|
Severity of Illness Index
|
Concept
|
Interleukin-23 Subunit p19
|
Concept
|
Red-Cell Aplasia, Pure
|
Concept
|
Glycogen Synthase Kinase 3
|
Concept
|
Vascular Endothelial Growth Factor Receptor-3
|
Concept
|
Glutamate Carboxypeptidase II
|
Concept
|
Taxoids
|
Concept
|
Xanthones
|
Concept
|
Proto-Oncogene Proteins c-cbl
|
Concept
|
Molecular Targeted Therapy
|
Concept
|
Rats
|
Concept
|
Chemoradiotherapy
|
Concept
|
SOX9 Transcription Factor
|
Concept
|
Benzodioxoles
|
Concept
|
High-Throughput Nucleotide Sequencing
|
Concept
|
Real-Time Polymerase Chain Reaction
|
Concept
|
Antibodies, Monoclonal, Humanized
|
Concept
|
CTLA-4 Antigen
|
Concept
|
Sex Factors
|
Concept
|
Spinal Cord Neoplasms
|
Concept
|
Spleen
|
Concept
|
Adaptor Proteins, Signal Transducing
|
Concept
|
Chemokine CXCL10
|
Concept
|
Chemokine CCL19
|
Concept
|
T-Lymphocytes, Cytotoxic
|
Concept
|
Temperature
|
Concept
|
Immunoblotting
|
Concept
|
Blotting, Western
|
Concept
|
Down-Regulation
|
Concept
|
HSP40 Heat-Shock Proteins
|
Concept
|
PTEN Phosphohydrolase
|
Concept
|
MutS Homolog 2 Protein
|
Concept
|
Survival Analysis
|
Concept
|
Integrin alphaXbeta2
|
Concept
|
Receptors, Lymphocyte Homing
|
Concept
|
Genes, myc
|
Concept
|
Tetradecanoylphorbol Acetate
|
Concept
|
Lymphoma, B-Cell
|
Concept
|
CD4-CD8 Ratio
|
Concept
|
Cyclosporine
|
Concept
|
Genes, RAG-1
|
Concept
|
Drug Monitoring
|
Concept
|
Enterococcus faecium
|
Concept
|
Transfection
|
Concept
|
Blotting, Northern
|
Concept
|
Treatment Failure
|
Concept
|
Ionomycin
|
Concept
|
Survival Rate
|
Concept
|
Transplantation Chimera
|
Concept
|
Coronavirus Infections
|
Concept
|
Skin Transplantation
|
Concept
|
Lymphocyte Subsets
|
Concept
|
Polymerase Chain Reaction
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
Concept
|
Intercellular Adhesion Molecule-1
|
Concept
|
Thy-1 Antigens
|
Concept
|
CD2 Antigens
|
Concept
|
Cell Polarity
|
Concept
|
Interferon-beta
|
Concept
|
Stromal Cells
|
Concept
|
CD3 Complex
|
Concept
|
Protein Prenylation
|
Concept
|
Dimerization
|
Concept
|
Myeloid Differentiation Factor 88
|
Concept
|
Leukocyte Common Antigens
|
Concept
|
Microsatellite Instability
|
Concept
|
Receptors, CXCR3
|
Concept
|
Receptors, CCR2
|
Concept
|
Chemokine CCL21
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
Concept
|
Calcium-Calmodulin-Dependent Protein Kinases
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 22
|
Concept
|
Immunological Synapses
|
Concept
|
Xenograft Model Antitumor Assays
|
Concept
|
Gene Targeting
|
Concept
|
Homeodomain Proteins
|
Concept
|
Statistics, Nonparametric
|
Concept
|
Genetic Heterogeneity
|
Concept
|
Cell Lineage
|
Concept
|
Peptide Library
|
Concept
|
Hematologic Neoplasms
|
Concept
|
Gadolinium DTPA
|
Concept
|
Cation Transport Proteins
|
Concept
|
Lymphangiogenesis
|
Concept
|
Vaccines, Subunit
|
Concept
|
JNK Mitogen-Activated Protein Kinases
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
Concept
|
T-Lymphocytes, Regulatory
|
Concept
|
STAT1 Transcription Factor
|
Concept
|
STAT5 Transcription Factor
|
Concept
|
Lymphohistiocytosis, Hemophagocytic
|
Concept
|
GRB2 Adaptor Protein
|
Concept
|
I-kappa B Kinase
|
Concept
|
gp100 Melanoma Antigen
|
Concept
|
B7-2 Antigen
|
Concept
|
Transcriptome
|
Concept
|
TNF-Related Apoptosis-Inducing Ligand
|
Concept
|
Granzymes
|
Concept
|
Genome-Wide Association Study
|
Concept
|
Immune Evasion
|
Concept
|
Citrus paradisi
|
Concept
|
Siblings
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
Concept
|
Pandemics
|
Concept
|
Tumor Microenvironment
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
Concept
|
Vascular Endothelial Growth Factor A
|
Concept
|
Programmed Cell Death 1 Receptor
|
Concept
|
Cell Line, Tumor
|
Concept
|
STAT6 Transcription Factor
|
Concept
|
bcl-Associated Death Protein
|
Concept
|
Toll-Like Receptor 9
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 3
|
Concept
|
Early Growth Response Protein 2
|
Concept
|
Forkhead Transcription Factors
|
Concept
|
Phospholipase C gamma
|
Concept
|
Kaplan-Meier Estimate
|
Concept
|
Plasma Membrane Calcium-Transporting ATPases
|
Concept
|
Amyloid Precursor Protein Secretases
|
Concept
|
Metagenome
|
Concept
|
Exosomes
|
Concept
|
MART-1 Antigen
|
Concept
|
Topoisomerase II Inhibitors
|
Concept
|
Antibodies
|
Concept
|
Azetidines
|
Concept
|
Binding, Competitive
|
Concept
|
Brain Neoplasms
|
Concept
|
Calcium
|
Concept
|
Cell Line
|
Concept
|
Cell Survival
|
Concept
|
Cells, Cultured
|
Concept
|
Chyle
|
Concept
|
Clinical Trials as Topic
|
Concept
|
Cloning, Molecular
|
Concept
|
Crosses, Genetic
|
Concept
|
Disease Models, Animal
|
Concept
|
Drug Administration Schedule
|
Concept
|
Enterovirus
|
Concept
|
Fever
|
Concept
|
Follow-Up Studies
|
Concept
|
Genotype
|
Concept
|
Glucose
|
Concept
|
Growth Substances
|
Concept
|
Hyperglycemia
|
Concept
|
Immunoglobulins
|
Concept
|
Lymphocyte Activation
|
Concept
|
Lymphocytes
|
Concept
|
Lymphoma, Non-Hodgkin
|
Concept
|
Magnetic Resonance Imaging
|
Concept
|
Metacarpus
|
Concept
|
Mice, Mutant Strains
|
Concept
|
Prospective Studies
|
Concept
|
Proto-Oncogenes
|
Concept
|
Recombinant Fusion Proteins
|
Concept
|
Respiration, Artificial
|
Concept
|
Retrospective Studies
|
Concept
|
Serine Endopeptidases
|
Concept
|
T-Lymphocytes
|
Concept
|
Thymus Gland
|
Concept
|
Uveal Neoplasms
|
Concept
|
Vaccines, Synthetic
|
Concept
|
CD4 Antigens
|
Concept
|
Gene Expression Regulation, Neoplastic
|
Concept
|
Immunophenotyping
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
Concept
|
Cytokines
|
Concept
|
Databases, Factual
|
Concept
|
Macrophage-Activating Factors
|
Concept
|
DNA Primers
|
Concept
|
Disease-Free Survival
|
Concept
|
Macrolides
|
Concept
|
CD5 Antigens
|
Concept
|
Viral Load
|
Concept
|
Quantitative Trait Loci
|
Concept
|
Epigenesis, Genetic
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
CARD Signaling Adaptor Proteins
|
Concept
|
p21-Activated Kinases
|
Concept
|
Patient Safety
|
Academic Article
|
Differential function of intestinal intraepithelial lymphocyte subsets.
|
Academic Article
|
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
|
Academic Article
|
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones.
|
Academic Article
|
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
|
Academic Article
|
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
|
Academic Article
|
Blocked Ras activation in anergic CD4+ T cells.
|
Academic Article
|
Rational development of tumour antigen-specific immunization in melanoma.
|
Academic Article
|
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response.
|
Academic Article
|
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity.
|
Academic Article
|
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.
|
Academic Article
|
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.
|
Academic Article
|
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
|
Academic Article
|
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.
|
Academic Article
|
Helper T cell differentiation is controlled by the cell cycle.
|
Academic Article
|
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.
|
Academic Article
|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
|
Academic Article
|
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.
|
Academic Article
|
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
|
Academic Article
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
Academic Article
|
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
|
Academic Article
|
Transplantation and the CD28/CTLA4/B7 pathway.
|
Academic Article
|
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
|
Academic Article
|
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
|
Academic Article
|
Differential activation of murine TH1 and TH2 clones.
|
Academic Article
|
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
|
Academic Article
|
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
|
Academic Article
|
T cell development and function in CrkL-deficient mice.
|
Academic Article
|
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL.
|
Academic Article
|
Integrating IL-12 into therapeutic cancer vaccines.
|
Academic Article
|
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.
|
Academic Article
|
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
|
Academic Article
|
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
|
Academic Article
|
Temozolomide for melanoma: new toxicities and new opportunities.
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
Academic Article
|
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes.
|
Academic Article
|
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
|
Academic Article
|
Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration.
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
Academic Article
|
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
|
Academic Article
|
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation.
|
Academic Article
|
CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.
|
Academic Article
|
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines.
|
Academic Article
|
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.
|
Academic Article
|
Update on vaccines for solid tumors.
|
Academic Article
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
|
Academic Article
|
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
|
Academic Article
|
On the TRAIL toward death receptor-based cancer therapeutics.
|
Academic Article
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
Academic Article
|
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones.
|
Academic Article
|
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells.
|
Academic Article
|
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.
|
Academic Article
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
Academic Article
|
Immune suppression in the tumor microenvironment.
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
Academic Article
|
Molecular regulation of T-cell anergy.
|
Academic Article
|
The p815 mastocytoma tumor model.
|
Academic Article
|
Production of TH1 and TH2 cell lines and clones.
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
Academic Article
|
Diagnosis and treatment of mycoplasma-contaminated cell cultures.
|
Academic Article
|
Diagnosis and treatment of Mycoplasma-contaminated cell cultures.
|
Academic Article
|
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
|
Academic Article
|
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
|
Academic Article
|
Melanoma presenting as circulating tumor cells associated with failed angiogenesis.
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
Academic Article
|
Diagnosis and treatment of mycoplasma-contaminated cell cultures.
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
Academic Article
|
Metabolic mechanisms of tumor resistance to T cell effector function.
|
Academic Article
|
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
|
Academic Article
|
Negative regulation of T-cell function by PD-1.
|
Academic Article
|
Peripheral survival of naïve CD8+ T cells.
|
Academic Article
|
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma.
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
Academic Article
|
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
|
Academic Article
|
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
|
Academic Article
|
Immune resistance orchestrated by the tumor microenvironment.
|
Academic Article
|
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha.
|
Academic Article
|
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
Academic Article
|
Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
|
Academic Article
|
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
|
Academic Article
|
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
|
Academic Article
|
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
|
Academic Article
|
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
|
Academic Article
|
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.
|
Academic Article
|
Emerging strategies in regulatory T-cell immunotherapies.
|
Academic Article
|
Costimulatory and coinhibitory receptors in anti-tumor immunity.
|
Academic Article
|
Molecular profiling of melanoma and the evolution of patient-specific therapy.
|
Academic Article
|
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.
|
Academic Article
|
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
|
Academic Article
|
The immune score as a new possible approach for the classification of cancer.
|
Academic Article
|
Innate immune sensing of cancer: clues from an identified role for type I IFNs.
|
Academic Article
|
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
|
Academic Article
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
Academic Article
|
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
|
Academic Article
|
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
|
Academic Article
|
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.
|
Academic Article
|
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells.
|
Academic Article
|
Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones.
|
Academic Article
|
Regulation of T-cell activation: differences among T-cell subsets.
|
Academic Article
|
Harnessing the immune response.
|
Academic Article
|
An adenoviral vector for probing promoter activity in primary immune cells.
|
Academic Article
|
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
Academic Article
|
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.
|
Academic Article
|
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
|
Academic Article
|
Defining the critical hurdles in cancer immunotherapy.
|
Academic Article
|
Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A.
|
Academic Article
|
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways.
|
Academic Article
|
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
|
Academic Article
|
From defined human tumor antigens to effective immunization?
|
Academic Article
|
The expanding universe of regulatory T cell subsets in cancer.
|
Academic Article
|
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
|
Academic Article
|
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.
|
Academic Article
|
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation.
|
Academic Article
|
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor.
|
Academic Article
|
Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways.
|
Academic Article
|
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
|
Academic Article
|
Expression and function of CTLA-4 in Th1 and Th2 cells.
|
Academic Article
|
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
|
Academic Article
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
Academic Article
|
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells.
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
Academic Article
|
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
|
Academic Article
|
Lymphoma-infiltrating immune cells.
|
Academic Article
|
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
|
Academic Article
|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
|
Academic Article
|
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
|
Academic Article
|
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
|
Academic Article
|
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
|
Academic Article
|
Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma.
|
Academic Article
|
Beta-catenin does not regulate memory T cell phenotype.
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
Academic Article
|
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.
|
Academic Article
|
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
|
Academic Article
|
Ocular melanoma metastasis to the cervical spine.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
[Case of foreign body in the brain].
|
Academic Article
|
[2- and multistage surgical procedures on the intestines].
|
Academic Article
|
[Parotitis as a postoperative complication].
|
Academic Article
|
[A case of effusion of chyle into the pleural and peritoneal cavity].
|
Academic Article
|
[Surgical treatment of a case of giant hypertrophy of the mandible].
|
Academic Article
|
[Osteoid osteoma].
|
Academic Article
|
[Indications concerning the management of patients with artificial anus].
|
Academic Article
|
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
|
Academic Article
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
|
Academic Article
|
Cancer classification using the Immunoscore: a worldwide task force.
|
Academic Article
|
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
|
Academic Article
|
Type I interferon response and innate immune sensing of cancer.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
|
Academic Article
|
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.
|
Academic Article
|
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
|
Academic Article
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
Academic Article
|
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
|
Academic Article
|
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
Academic Article
|
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature.
|
Academic Article
|
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
|
Academic Article
|
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.
|
Academic Article
|
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
|
Academic Article
|
New perspectives on type I IFNs in cancer.
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Academic Article
|
Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation.
|
Academic Article
|
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
|
Academic Article
|
Innate immune recognition of cancer.
|
Academic Article
|
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
|
Academic Article
|
T cell-NF-?B activation is required for tumor control in vivo.
|
Academic Article
|
Innate and adaptive immune cells in the tumor microenvironment.
|
Academic Article
|
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
|
Academic Article
|
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.
|
Academic Article
|
Rational combinations of immunotherapeutics that target discrete pathways.
|
Academic Article
|
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
|
Academic Article
|
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
|
Academic Article
|
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
|
Academic Article
|
The STING pathway and the T cell-inflamed tumor microenvironment.
|
Academic Article
|
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
|
Academic Article
|
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity.
|
Academic Article
|
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
A new paradigm for tumor immune escape: ß-catenin-driven immune exclusion.
|
Academic Article
|
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
Academic Article
|
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
Academic Article
|
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
|
Academic Article
|
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
Academic Article
|
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.
|
Academic Article
|
Germ Warfare.
|
Academic Article
|
MYC - a thorn in the side of cancer immunity.
|
Academic Article
|
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.
|
Academic Article
|
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
|
Academic Article
|
The composition of the microbiota modulates allograft rejection.
|
Academic Article
|
The host STING pathway at the interface of cancer and immunity.
|
Academic Article
|
Manipulating the microbiome to improve the efficacy of immunotherapy.
|
Academic Article
|
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
|
Academic Article
|
Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.
|
Academic Article
|
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
|
Academic Article
|
Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
|
Academic Article
|
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
|
Academic Article
|
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
|
Academic Article
|
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
|
Academic Article
|
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
|
Academic Article
|
Innate immune signaling and regulation in cancer immunotherapy.
|
Academic Article
|
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
|
Academic Article
|
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
Academic Article
|
Tumor-intrinsic oncogene pathways mediating immune avoidance.
|
Academic Article
|
Phase 2 trial of talabostat in stage IV melanoma.
|
Academic Article
|
Reciprocal expression of indoleamine-2,3-dioxygenase (IDO) and arginase-I in metastatic melanoma tumors.
|
Academic Article
|
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
|
Academic Article
|
Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies.
|
Academic Article
|
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma.
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
Academic Article
|
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.
|
Academic Article
|
Impact of oncogenic pathways on evasion of antitumour immune responses.
|
Academic Article
|
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
|
Academic Article
|
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
|
Academic Article
|
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
Academic Article
|
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.
|
Academic Article
|
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
Academic Article
|
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
|
Academic Article
|
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
|
Academic Article
|
Back from the dead: TIL apoptosis in cancer immune evasion.
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
Academic Article
|
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Fast Forward - Neoadjuvant Cancer Immunotherapy.
|
Academic Article
|
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
|
Academic Article
|
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
Academic Article
|
Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance.
|
Academic Article
|
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
|
Academic Article
|
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
|
Academic Article
|
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
|
Academic Article
|
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
|
Academic Article
|
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
|
Academic Article
|
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
|
Academic Article
|
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
|
Academic Article
|
STING pathway agonism as a cancer therapeutic.
|
Academic Article
|
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
|
Academic Article
|
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
|
Academic Article
|
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
|
Academic Article
|
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
|
Academic Article
|
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells.
|
Academic Article
|
Exploring the emerging role of the microbiome in cancer immunotherapy.
|
Academic Article
|
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
|
Academic Article
|
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
|
Academic Article
|
Strategies to overcome resistance to PD-1 inhibitors.
|
Academic Article
|
cDC1 dysregulation in cancer: An opportunity for intervention.
|
Academic Article
|
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
|
Academic Article
|
Immunotherapy with a sting.
|
Academic Article
|
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
|
Academic Article
|
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion.
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
Academic Article
|
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
|
Academic Article
|
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma.
|
Academic Article
|
Sensitive detection and quantification of SARS-CoV-2 in saliva.
|
Academic Article
|
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
|
Academic Article
|
Frank W. Fitch (1929-2021).
|
Academic Article
|
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
|
Academic Article
|
Sensitive detection and quantification of SARS-CoV-2 in saliva.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
|
Academic Article
|
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
|
Academic Article
|
ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients.
|
Academic Article
|
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
|
Academic Article
|
SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II.
|
Academic Article
|
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction.
|
Academic Article
|
PAK4 as a cancer immune-evasion target.
|
Academic Article
|
Dietary modulation of the gut microbiome as an immunoregulatory intervention.
|
Academic Article
|
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
|
Academic Article
|
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
|
Academic Article
|
Microbiome-based interventions: therapeutic strategies in cancer immunotherapy.
|
Academic Article
|
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools.
|
Academic Article
|
CXCL9 and CXCL10 bring the heat to tumors.
|
Academic Article
|
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines.
|
Academic Article
|
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
|
Academic Article
|
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
|
Academic Article
|
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents.
|
Academic Article
|
Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity.
|
Academic Article
|
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.
|
Academic Article
|
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
|
Concept
|
Fingolimod Hydrochloride
|
Concept
|
Imatinib Mesylate
|
Concept
|
Gastrointestinal Microbiome
|
Concept
|
Rituximab
|
Concept
|
Abatacept
|
Concept
|
Patient Reported Outcome Measures
|
Concept
|
Bifidobacterium longum
|
Concept
|
Enhancer of Zeste Homolog 2 Protein
|
Concept
|
Positron Emission Tomography Computed Tomography
|
Concept
|
Pathologists
|
Concept
|
Placenta Growth Factor
|
Concept
|
MDS1 and EVI1 Complex Locus Protein
|
Concept
|
Antineoplastic Agents, Immunological
|
Concept
|
Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein
|
Concept
|
B-Cell CLL-Lymphoma 10 Protein
|
Concept
|
Ipilimumab
|
Concept
|
Regulatory-Associated Protein of mTOR
|
Concept
|
MCF-7 Cells
|
Concept
|
Coxsackie and Adenovirus Receptor-Like Membrane Protein
|
Concept
|
CRISPR-Cas Systems
|
Concept
|
Microbiota
|
Concept
|
Histocompatibility Antigen H-2D
|
Concept
|
Extracellular Traps
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|
Academic Article
|
Tissue-resident memory T cells in immune-related adverse events: friend or foe?
|
Academic Article
|
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
|
Academic Article
|
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
|
Academic Article
|
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation.
|
Academic Article
|
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.
|
Academic Article
|
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
|
Academic Article
|
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy.
|